Skip to main content

Esophagitis, Reflux

1
Pipeline Programs
2
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Zeria Pharmaceutical
1 program
1
Z-215 10mgPhase 21 trial
Active Trials
NCT02463643Completed503Est. Mar 2017
Takeda
TakedaTOKYO, Japan
1 program
Dexlansoprazole MRPHASE_35 trials
Active Trials
NCT00847210Completed36Est. Sep 2009
NCT00847808Completed178Est. Apr 2010
NCT00321737Completed445Est. May 2007
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaDexlansoprazole MR
TakedaDexlansoprazole MR
TakedaDexlansoprazole MR
TakedaDexlansoprazole MR
TakedaDexlansoprazole MR
Zeria PharmaceuticalZ-215 10mg
TakedaDexlansoprazole MR

Clinical Trials (7)

Total enrollment: 5,845 patients across 7 trials

NCT00847808TakedaDexlansoprazole MR

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Start: Feb 2009Est. completion: Apr 2010178 patients
Phase 3Completed
NCT00321737TakedaDexlansoprazole MR

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Start: May 2006Est. completion: May 2007445 patients
Phase 3Completed
NCT00255190TakedaDexlansoprazole MR

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Start: Jan 2006Est. completion: Jun 2008591 patients
Phase 3Completed
NCT00251693TakedaDexlansoprazole MR

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Start: Dec 2005Est. completion: Jan 20072,038 patients
Phase 3Completed
NCT00251719TakedaDexlansoprazole MR

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Start: Dec 2005Est. completion: Jan 20072,054 patients
Phase 3Completed
NCT02463643Zeria PharmaceuticalZ-215 10mg

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Start: May 2015Est. completion: Mar 2017503 patients
Phase 2Completed
NCT00847210TakedaDexlansoprazole MR

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

Start: May 2009Est. completion: Sep 200936 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.